Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Multicenter Randomized Trial to Assess the Efficacy and Safety of First Line Nivolumab in Combination with Paclitaxel in Subjects with R/M HNSCC Unable for Cisplatin-based Chemotherapy (NIVOTAX)

Next Previous
Search
Trial Profile

Phase II Multicenter Randomized Trial to Assess the Efficacy and Safety of First Line Nivolumab in Combination with Paclitaxel in Subjects with R/M HNSCC Unable for Cisplatin-based Chemotherapy (NIVOTAX)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Paclitaxel (Primary) ; Cetuximab
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Therapeutic Use
  • Acronyms NIVOTAX

    • Most Recent Events

    • 02 Sep 2024 Status changed from active, no longer recruiting to completed.
    • 07 Jun 2022 Pathology outcomes from the NIVOTAX trial, results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
    • 08 Nov 2021 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top